cometadata/datacite-rtg-text-other-reclassification-records huggingface dataset:
Additional file 1: of Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy
Creators: name: Brachat, Arndt
name: Grom, Alexei
name: Wulffraat, Nico
name: Brunner, Hermine
name: Quartier, Pierre
name: Brik, Riva
name: McCann, Liza
name: Ozdogan, Huri
name: Rutkowska-Sak, Lidia
name: Rayfel Schneider
name: Gerloni, Valeria
name: Harel, Liora
name: Terreri, Maria
name: Houghton, Kristin
name: Joos, Rik
name: Kingsbury, Daniel
name: Lopez-Benitez, Jorge
name: Bek, Stephan
name: Schumacher, Martin
name: Marie-Anne Valentin
name: Gram, Hermann
name: Abrams, Ken
name: Martini, Alberto
name: Lovell, Daniel
name: Nanguneri Nirmala
name: Ruperto, Nicolino
Publisher: name: Figshare
Year: 2017
Subjects: subject: Medicine
subject: Microbiology
subject: FOS: Biological sciences
subject: Genetics
subject: Pharmacology
subject: Immunology
subject: FOS: Clinical medicine
subject: Developmental Biology
subject: Marine Biology
subject: Science Policy
subject: Infectious Diseases
subject: FOS: Health sciences

description: Table S1 Definition of adapted ACR JIA response. Table S2 Genes with â Ľ3-fold differential expression between patients with SJIA and healthy controls, prior to canakinumab treatment. Table S3 List of independent ethics committees or institutional review boards (trial 1). Table S4 List of independent ethics committees or institutional review boards (trial 2). (DOCX 53 kb)
Additional file 5: Figure S5. of Evolutional dynamics of 45S and 5S ribosomal DNA in ancient allohexaploid Atropa belladonna
Creators: name: Volkov, Roman
name: Panchuk, Irina
name: Borisjuk, Nikolai
name: Hosiawa-Baranska, Marta
name: Maluszynska, Jolanta
name: Hemleben, Vera
Publisher: name: Figshare
Year: 2017
Subjects: subject: Biophysics
subject: Biochemistry
subject: 29999 Physical Sciences not elsewhere classified
subject: FOS: Physical sciences
subject: Microbiology
subject: FOS: Biological sciences
subject: Cell Biology
subject: Genetics
subject: Molecular Biology
subject: Biotechnology
subject: Evolutionary Biology
subject: 80699 Information Systems not elsewhere classified
subject: FOS: Computer and information sciences
subject: Developmental Biology
subject: 110309 Infectious Diseases
subject: FOS: Health sciences
subject: Computational Biology

description: Nucleotide sequence comparison of 45S IGS structural region VI (SR VI) of Atropa belladonna (Abel) and corresponding regions of Solanum bulbocastanum (Sblb) and Nicotiana tomentosiformis (Ntom). (PDF 43 kb)
Cost-effectiveness of volume computed tomography in lung cancer screening: a cohort simulation based on Nelson study outcomes
Creators: name: Pan, Xuanqi
name: Dvortsin, Evgeni
name: Baldwin, David R.
name: Groen, Harry J. M.
name: Ramaker, Dianne
name: Ryan, James
name: Berge, Hilde ten
name: Velikanova, Rimma
name: Oudkerk, Matthijs
name: Postma, Maarten J.
Publisher: name: Taylor & Francis
Year: 2023
Subjects: subject: Medicine
subject: Physiology
subject: FOS: Biological sciences
subject: Pharmacology
subject: Biotechnology
subject: Sociology
subject: FOS: Sociology
subject: Biological Sciences not elsewhere classified
subject: Cancer
subject: Science Policy

description: This study aimed to evaluate the cost-effectiveness of lung cancer screening (LCS) with volume-based low-dose computed tomography (CT) versus no screening for an asymptomatic high-risk population in the United Kingdom (UK), utilising the long-term insights provided by the NELSON study, the largest European randomized control trial investigating LCS. A cost-effectiveness analysis was conducted using a decision tree and a state-transition Markov model to simulate the identification, diagnosis, and treatments for a lung cancer high-risk population, from a UK National Health Service (NHS) perspective. Eligible participants underwent annual volume CT screening and were compared to a cohort without the option of screening. Screen-detected lung cancers, costs, quality-adjusted life years (QALYs), and the incremental cost-effectiveness ratio (ICER) were predicted. Annual volume CT screening of 1.3 million eligible participants resulted in 96,474 more lung cancer cases detected in early stage, and 73,825 fewer cases in late stage, leading to 53,732 premature lung cancer deaths averted and 421,647 QALYs gained, compared to no screening. The ICER was £5,455 per QALY. These estimates were robust in sensitivity analyses. Lack of long-term survival data for lung cancer patients; deficiency in rigorous micro-costing studies to establish detailed treatment costs inputs for lung cancer patients. Annual LCS with volume-based low-dose CT for a high-risk asymptomatic population is cost-effective in the UK, at a threshold of £20,000 per QALY, representing an efficient use of NHS resources with substantially improved outcomes for lung cancer patients, as well as additional societal and economic benefits for society as a whole. These findings advocate evidence-based decisions for the potential implementation of a nationwide LCS in the UK.
Bannatettix guangxiensis Zheng & Jiang 1997
Creators: name: Deng, Wei-An
name: Zheng, Zhe-Min
name: Li, Xiao-Dong
name: Lin, Min-Ping
name: Wei, Shi-Zhen
name: Yuan, Bao-Dong
name: Lin, Li-Liang
Publisher: name: Zenodo
Year: 2015
Subjects: Biodiversity
Taxonomy
Animalia
Arthropoda
Insecta
Orthoptera
Tetrigidae
Bannatettix
Bannatettix guangxiensis

description: 82. Bannatettix guangxiensis Zheng & Jiang, 1997
Specimens examined. 10 ♂ 6♀, Fangcheng (Dongzhong), 21°38’N, 107°38’E, 500m alt, 21 Jul. 2013, collected by Da-Heng Yao.
Distribution. China (Guangxi).
description: Published as part of Deng, Wei-An, Zheng, Zhe-Min, Li, Xiao-Dong, Lin, Min-Ping, Wei, Shi-Zhen, Yuan, Bao-Dong & Lin, Li-Liang, 2015, The groundhopper fauna (Orthoptera: Tetrigidae) of Shiwanshan (Guangxi, China) with description of three new species, pp. 151-178 in Zootaxa 3925 (2) on page 174, DOI: 10.11646/zootaxa.3925.2.1, http://zenodo.org/record/243557
RDA TIGER D2.1 Communication Toolkit (version 2.0)
Creators: name: Delipalta, Alexandra
name: Halbert, Genevieve
Publisher: name: Zenodo
Year: 2024
Subjects: project management
project communication
communication toolkit
communication
Research Data Alliance
EOSC

description: The RDA TIGER Communication Toolkit builds on the RDA brand, utilises existing materials and expands them where appropriate. This document outlines communications and marketing materials that will be used during the project lifetime to facilitate RDA TIGER service awareness primarily, but also to support the RDA TIGER individual services.

This is the updated RDA TIGER Communication Toolkit that builds upon lessons learned in the first 2 years of project implementation and updates the original RDA TIGER Communication Toolkit published in June 2023 (https://doi.org/10.5281/zenodo.8058923).
Post-approval indications and clinical trials for cardiovascular drugs: some implications of the US Inflation Reduction Act
Creators: name: Grabowski, Henry
name: Long, Genia
Publisher: name: Taylor & Francis
Year: 2024
Subjects: subject: Medicine
subject: Pharmacology
subject: Cancer
subject: Science Policy
subject: Infectious Diseases
subject: FOS: Health sciences
subject: Virology
subject: Computational Biology

description: To describe the historical baseline landscape of cardiovascular drug post-approval activity, including the number and timing of post-approval clinical trials and approved indications. The US Inflation Reduction Act of 2022 (IRA) Drug Price Negotiation Program (DPNP) and its Maximum Fair Prices (MFPs) will affect incentives for investment in post-approval activity such as clinical trials for new indications. While three of the first ten drugs selected for the DPNP and MFP-setting are cardiovascular or antithrombotic drugs, limited attention has been paid to potential cardiovascular drug impacts, and to post-approval innovation. For the 65 drugs originally approved by the FDA from 1995 through 2021 for a cardiovascular or antithrombotic indication (60 small molecules and 5 biologics), we develop a novel dataset of industry-sponsored, post-approval clinical trials and FDA-approved label changes for new indications. We analyze their number and timing relative to DPNP drug selection and MFP implementation dates, by drug approval-year cohort. We find 49% of indications were awarded and 76% of industry-funded clinical trials were completed post-approval, reaching 98% of trials for drugs in the earliest 1995–99 cohort. For the 60 small molecules, 76% of post-approval trials ended five years or more after original drug approval, 65% ended seven or more years after original drug approval (i.e. after potential DPNP selection), and 53% nine or more years after original drug approval (i.e. after potential MFP implementation). Post-approval FDA indication approvals and clinical trial starts and primary completion dates often occurred after or near new DPNP selection and MFP implementation dates. This has economic consequences for future investment incentives. Post-approval trials for small molecules, longer-duration trials, and larger-enrollment trials, and post-approval indications focused on limited patient populations and older patients could face particular economic challenges.
Cost-effectiveness of empagliflozin as add-on to standard of care for chronic kidney disease management in the United Kingdom
Creators: name: Ramos, Mafalda
name: Gerlier, Laetitia
name: Uster, Anastasia
name: Muttram, Louise
name: Frankel, Andrew H.
name: Lamotte, Mark
Publisher: name: Taylor & Francis
Year: 2024
Subjects: subject: Medicine
subject: Pharmacology
subject: Sociology
subject: FOS: Sociology
subject: Biological Sciences not elsewhere classified
subject: Marine Biology
subject: Science Policy
subject: Infectious Diseases
subject: FOS: Health sciences

description: The sodium-glucose co-transporter-2 inhibitor empagliflozin was approved for treatment of adults with chronic kidney disease (CKD) on the basis of its demonstrated ability to slow CKD progression and reduce the risk of cardiovascular death. This analysis was performed to assess the cost-effectiveness of empagliflozin plus standard of care (SoC) vs SoC alone in the treatment of CKD in the UK. A comprehensive, patient-level CKD progression model that simulates the evolution of risk factors for disease progression based on CKD-specific equations and clinical data was used to project a broad range of CKD-related complications. Patient baseline characteristics, distribution across Kidney Disease Improving Global Outcomes (KDIGO) health states, and changes in estimated glomerular filtration rate (eGFR), urine albumin-creatinine ratio (uACR), and other parameters while on treatment were derived from the EMPA-KIDNEY trial. UK cost and utilities/disutilities were sourced from the literature. Univariate and probabilistic sensitivity analyses were conducted. Annual discounting of 3.5% was applied on costs and outcomes. Over a 50-year horizon, SoC resulted in per-patient costs, life years, and QALYs of £95,930, 8.55, and 6.28, respectively. Empagliflozin plus SoC resulted in an incremental gain in life years (+1.04) and QALYs (+0.84), while decreasing per-patient costs by £6,019. Empagliflozin was more effective and less costly (dominant) with a net monetary benefit of £22,849 at the willingness-to-pay threshold of £20,000. Although treatment cost was higher for empagliflozin, this was more than offset by savings in kidney replacement therapy. Empagliflozin remained highly cost-effective in patients with and without diabetes, and across scenario and sensitivity analyses. This analysis is limited by reliance on short-term clinical trial data and by uncertainties in modelling CKD progression. Empagliflozin as an add-on to SoC for treatment of adults with CKD represents cost-effective use of UK National Health Service (NHS) resources.
Additional file 5: Figure S5. of Evolutional dynamics of 45S and 5S ribosomal DNA in ancient allohexaploid Atropa belladonna
Creators: name: Volkov, Roman
name: Panchuk, Irina
name: Borisjuk, Nikolai
name: Hosiawa-Baranska, Marta
name: Maluszynska, Jolanta
name: Hemleben, Vera
Publisher: name: Figshare
Year: 2017
Subjects: subject: Biophysics
subject: Biochemistry
subject: 29999 Physical Sciences not elsewhere classified
subject: FOS: Physical sciences
subject: Microbiology
subject: FOS: Biological sciences
subject: Cell Biology
subject: Genetics
subject: Molecular Biology
subject: Biotechnology
subject: Evolutionary Biology
subject: 80699 Information Systems not elsewhere classified
subject: FOS: Computer and information sciences
subject: Developmental Biology
subject: Infectious Diseases
subject: FOS: Health sciences
subject: Computational Biology

description: Nucleotide sequence comparison of 45S IGS structural region VI (SR VI) of Atropa belladonna (Abel) and corresponding regions of Solanum bulbocastanum (Sblb) and Nicotiana tomentosiformis (Ntom). (PDF 43 kb)
Additional file 3 of Comparison of methods for estimating the attributable risk in the context of survival analysis
Creators: name: Malamine Gassama
name: Bénichou, Jacques
name: Dartois, Laureen
name: Thiébaut, Anne
Publisher: name: Figshare
Year: 2017
Subjects: subject: Medicine
subject: Genetics
subject: FOS: Biological sciences
subject: Molecular Biology
subject: Biotechnology
subject: 69999 Biological Sciences not elsewhere classified
subject: 19999 Mathematical Sciences not elsewhere classified
subject: FOS: Mathematics

description: Simulation results for the estimation of attributable risk A(.) under proportional hazards, constant baseline hazard (γ=1) with regression parameter β=0 and probability of exposure q=0.5. (PDF 20.1 kb)
MOESM2 of Recent uptake of intermittent preventive treatment during pregnancy with sulfadoxineâ  pyrimethamine is associated with increased prevalence of Pfdhfr mutations in Bobo-Dioulasso, Burkina Faso
Creators: name: Mamoudou Cisse
name: Awandare, Gordon
name: Alamissa Soulama
name: Halidou Tinto
name: Hayette, Marie-Pierre
name: GuiguemdĂŠ, Robert
Publisher: name: Figshare
Year: 2017
Subjects: subject: Medicine
subject: Genetics
subject: FOS: Biological sciences
subject: Molecular Biology
subject: Evolutionary Biology
subject: 69999 Biological Sciences not elsewhere classified
subject: Cancer
subject: Infectious Diseases
subject: FOS: Health sciences
subject: Virology
subject: Computational Biology

description: Additional file 2: Table S2. Association between the number of SP doses and the Pfdhfr intermediate-to-high resistance. The data provided showed the association between the number of SP doses and the prevalence of at least 2 Pfdhfr mutations using a logistic regression model adjusted for residence, age, and gravidity.
Additional file 1: of Synthetic photosynthetic consortia define interactions leading to robustness and photoproduction
Creators: name: Hays, Stephanie
name: Yan, Leo
name: Silver, Pamela
name: Ducat, Daniel
Publisher: name: Figshare
Year: 2017
Subjects: subject: Medicine
subject: Molecular Biology
subject: 59999 Environmental Sciences not elsewhere classified
subject: FOS: Earth and related environmental sciences
subject: Sociology
subject: FOS: Sociology
subject: 69999 Biological Sciences not elsewhere classified
subject: FOS: Biological sciences
subject: 80699 Information Systems not elsewhere classified
subject: FOS: Computer and information sciences
subject: 19999 Mathematical Sciences not elsewhere classified
subject: FOS: Mathematics
subject: Developmental Biology
subject: Computational Biology

description: Contains supplementary figures S1-S15 as well as the mathematical framework used to investigate microbial community interactions. (DOCX 75744 kb)
Aceras anthropophorum W. T. Aiton
Creators: name: Konrad Lauber
name: Gerhart Wagner
name: Andreas Gygax
Publisher: name: Haupt Verlag
Year: 2018
Subjects: Biodiversity
Taxonomy
Plantae
Tracheophyta
Liliopsida
Asparagales
Orchidaceae
Aceras
Aceras anthropophorum

description: Aceras anthropophorum (L.) W. T. Aiton
Artbeschreibung: Stängel 20-40 cm hoch, nur unten beblättert. Blätter den Stängel scheidig umfassend. Blütenstand schlank und lang zylindrisch, vielblütig. Perigonblätter gelbgrün, zu einem Helm zusammenneigend, die 3 äusseren oval, oft braunviolett berandet, die beiden inneren schmal-lanzettlich. Lippe ca. 10 mm lang, gelbgrün bis rotbraun, mit ca. 1 mm breitem, 2spaltigem Mittelabschnitt und ca. 0,5 mm breiten Seitenabschnitten. Kein Sporn.
Blütezeit: 5-6
Standort und Verbreitung in der Schweiz: Magerwiesen, lichte Laubmischwälder / kollin(-montan) / J, MW, ANW, VS, sonst vereinzelt
Verbreitung global: Mediterran
Ökologische Zeigerwerte nach Landolt & al. (2010)
BodenfaktorenKlimafaktorenSalztoleranzFeuchtezahl Ffrisch; Feuchtigkeit mässig wechselnd (± 1-2 Stufen)Lichtzahl LhellSalzzeichen--Reaktionszahl Rneutral bis basisch (pH 5.5-8.5)Temperaturzahl Twarm-kollinNährstoffzahl NnährstoffarmKontinentalitätszahl Ksubozeanisch (hohe Luftfeuchtigkeit, geringe Temperaturschwankungen, eher milde Winter)
Volksname Deutscher Name: Ohnsporn, Puppenorchis, Spornlos Nom français: Acéras homme pendu Nome italiano: Ballerina
description: Published as part of Konrad Lauber, Gerhart Wagner & Andreas Gygax, 2018, Flora Helvetica - Orchidaceae, pp. 1324-1362 in Flora Helvetica, Bern :Haupt Verlag on page 1342
title: Transfer graph feature alignment guided multi-source domain adaptation network for machinery fault diagnosis
Creators: name: Liu, Zhengwu
name: Zhong, Xiang
name: Shao, Haidong
name: Yan, Shen
name: Liu, Bin
Publisher: name: Strathprints - University of Strathclyde
Year: 2024

description: In recent years, the application of unsupervised multi-source domain adaptation (MSDA) techniques for fault diagnosis has gained significant traction. Current research typically overlooks or fails to effectively capture critical data structure information during feature extraction. Another challenge is optimising the integration of information from multiple source domains to diagnose the target domain while avoiding negative transfer. To address these challenges, this study proposes a transfer graph feature alignment guided multi-source domain adaptation network (MDTGAL). In the proposed method, a transfer graph sample generator module (GSG) is constructed to model the data structure between source and target domains, and multiple graph feature extractors are employed to learn the data structure information from different domain combinations. A regularisation technique is introduced to extract the domain-invariant features by aligning the parameters across multiple independent graph feature extractors. In addition, a weighted soft-voting mechanism based on the polynomial kernel-induced maximum mean difference metric (PK-MMD) is designed to fuse the outputs from multiple classifiers, to comprehensively account for the influence of each source domain. The proposed method was tested on multi-source domain transfer tasks involving various operating conditions of rotating machinery. The experimental results demonstrate that the MDTGAL exhibits superior cross-domain diagnostic performance, outperforming existing mainstream methods. In addition, this study explored the impact of varying numbers of source domains on the diagnostic accuracy of the target domain, providing insights into selecting the correct number of source domains for specific MSDA tasks.
Anacamptis pyramidalis Rich.
Creators: name: Konrad Lauber
name: Gerhart Wagner
name: Andreas Gygax
Publisher: name: Haupt Verlag
Year: 2018
Subjects: Biodiversity
Taxonomy
Plantae
Tracheophyta
Liliopsida
Asparagales
Orchidaceae
Anacamptis
Anacamptis pyramidalis

description: Anacamptis pyramidalis (L.) Rich.
Artbeschreibung: Stängel 20-60 cm hoch, mit lanzettlichen, nach oben kleiner werdenden Blättern. Blütenstand kegel- bis länglich eiförmig, dichtblütig, 4-8 cm lang. Die 3 äusseren Perigonblätter abstehend, 2 inneren zusammenneigend. Lippe im äussersten Drittel 3teilig, am Grund mit 2 vorspringenden Platten. Sporn fadenförmig, 10-14 mm lang, horizontal oder abwärts gerichtet.
Standort und Verbreitung in der Schweiz: Magerwiesen, Weiden /
Ökologische Zeigerwerte nach Landolt & al. (2010)
BodenfaktorenKlimafaktorenSalztoleranzFeuchtezahl Fmässig trocken; Feuchtigkeit mässig wechselnd (± 1-2 Stufen)Lichtzahl LhellSalzzeichen--Reaktionszahl Rbasisch (pH 6.5->8.5)Temperaturzahl Tunter-montan und ober-kollinNährstoffzahl NnährstoffarmKontinentalitätszahl Ksubkontinental (niedrige relative Luftfeuchtigkeit, grosse Temperaturschwankungen, eher kalte Winter)
Volksname Deutscher Name: Spitzorchis, Kamm-Knabenkraut Nom français: Orchis pyramidal Nome italiano: Orchide
description: Published as part of Konrad Lauber, Gerhart Wagner & Andreas Gygax, 2018, Flora Helvetica - Orchidaceae, pp. 1324-1362 in Flora Helvetica, Bern :Haupt Verlag on page 1342
Schizopyga flavifrons Holmgren 1856
Creators: name: Varga, Oleksandr
Publisher: name: Zenodo
Year: 2019
Subjects: Biodiversity
Taxonomy
Animalia
Arthropoda
Insecta
Hymenoptera
Ichneumonidae
Schizopyga
Schizopyga flavifrons

description: Schizopyga flavifrons Holmgren, 1856
Records. New record.
Material examined. Donetsk Reg.: 1 ♂, Blagodatne, SN, 11.vi.1975; Khmelnytskyi Reg.: 1 ♀, Shydlivtsi, SN, 28.vii.1988, leg. V. Tolkanitz.
Distribution. Oriental and Palaearctic Regs; Ukraine: Donetsk and Khmelnytskyi Regs.
Biology. CEMF, PS. June–July.
description: Published as part of Varga, Oleksandr, 2019, Taxonomy and distribution of pimpline parasitoids (Hymenoptera, Ichneumonidae, Pimplinae) in Ukraine, pp. 1-65 in Zootaxa 4693 (1) on page 41, DOI: 10.11646/zootaxa.4693.1.1, http://zenodo.org/record/3529018
Additional file 1: of Acute pancreatitis after thoracic duct ligation for iatrogenic chylothorax. A case report
Creators: name: Bédat, Benoît
name: Scarpa, Cosimo
name: Sadowski, Samira
name: Triponez, Frédéric
name: Karenovics, Wolfram
Publisher: name: Figshare
Year: 2017
Subjects: subject: Biophysics
subject: Biochemistry
subject: Medicine
subject: Cell Biology
subject: Physiology
subject: FOS: Biological sciences
subject: Biotechnology
subject: 39999 Chemical Sciences not elsewhere classified
subject: FOS: Chemical sciences
subject: Immunology
subject: FOS: Clinical medicine
subject: 69999 Biological Sciences not elsewhere classified
subject: Developmental Biology
subject: Science Policy
subject: Hematology
subject: 110309 Infectious Diseases
subject: FOS: Health sciences

description: Description of data : Blood test results 1 day after the onset of the abdominal pain. WBC, white blood count; CRP, C-reactive protein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; γGT, gamma-glutamyl transpeptidase; AP, alkaline phosphatase; IgG, immunoglobulin G. (DOCX 14 kb)
Additional file 3: Table S2. of Appropriate NH4
                     +: NO3
                     â   ratio improves low light tolerance of mini Chinese cabbage seedlings
Creators: name: Linli Hu
name: Weibiao Liao
name: Dawuda, Mohammed
name: Jihua Yu
name: Lv, Jian
Publisher: name: Figshare
Year: 2017
Subjects: subject: Space Science
subject: Microbiology
subject: FOS: Biological sciences
subject: Cell Biology
subject: Genetics
subject: Evolutionary Biology
subject: 39999 Chemical Sciences not elsewhere classified
subject: FOS: Chemical sciences
subject: Ecology
subject: Immunology
subject: FOS: Clinical medicine
subject: 69999 Biological Sciences not elsewhere classified
subject: Developmental Biology
subject: Marine Biology

description: Primer sequences, annealing temperature and Genebank accession number of the rbcL, rbcS, GAPDH, FBPase, FBA, TK and actin gene sequences. (DOCX 18 kb)
Cost-effectiveness analysis of sodium zirconium cyclosilicate for hyperkalemia among patients with chronic kidney disease or heart failure in Kuwait
Creators: name: Elsisi, Gihan Hamdy
name: Ibrahim, Mohamed M.
name: Al-Humood, Khaldoon
name: Al-Yousef, Anas
Publisher: name: Taylor & Francis
Year: 2024
Subjects: Medicine
Biological Sciences not elsewhere classified
Marine Biology
Cancer
Science Policy

description: Introduction: Our model was conducted from Kuwaiti payer’s perspective to provide evidence on the cost-effectiveness of Sodium zirconium cyclosilicate (SZC) versus patiromer to correct and maintain serum potassium (K+) in combination with renin‐angiotensin‐aldosterone system inhibitors (RAASis) with different dose titration in patients with chronic kidney disease/heart failure (CKD/HF) with/without renal replacement therapy (RRT). Methodology: The model was developed as a patient-level, fixed-time increment stochastic simulation to simulate the complexity of disease, including multiple coexisting and competing conditional risks. This model was established to compare SZC versus patiromer as a treatment for hyperkalemia (HK) among adult populations with underlying conditions of advanced CKD stages 3a–5 or HF to correct and maintain serum K + over a lifetime horizon. The clinical outcomes of SZC and patiromer were demonstrated through arm-specific K + trajectories extracted from the HARMONIZE trial and OPAL-HK trial, respectively. The utility data was captured from different studies. Direct medical cost was captured from local data from Kuwaiti hospitals. Sensitivity analyses were conducted to assess the uncertainty in the model. Results: Within different scenarios of CKD/HF, SZC was a cost-saving option, with/without RRT, whether one-off administration or repeated administration, except for one-off treatment administration among the HF cohort, which generated an incremental cost effectiveness ratio of KWD 331/quality adjusted life year (QALY). The incremental QALY of SZC ranged from 0.007 to 0.202. In addition, the savings observed with SZC fall within a range of KWD -60 to KWD -1,235 at serum K+ ≥ 5.1 mmol/L. Conclusion: The evidence generated by our model recommends the inclusion of SZC as a treatment option to correct HK and maintain normal serum K + level for CKD/HF patients within the Kuwaiti healthcare system. The costs saved from reducing frequent HK episodes, RAASis discontinuation/down titration, major cardiovascular events, and hospitalization offset the drug acquisition cost of SZC.
Anacamptis pyramidalis subsp. pyramidalis
Creators: name: Konrad Lauber
name: Gerhart Wagner
name: Andreas Gygax
Publisher: name: Haupt Verlag
Year: 2018
Subjects: Biodiversity
Taxonomy
Plantae
Tracheophyta
Liliopsida
Asparagales
Orchidaceae
Anacamptis
Anacamptis pyramidalis
Anacamptis pyramidalis (l.) rich. subsp. pyramidalis

description: Anacamptis pyramidalis (L.) Rich. subsp. pyramidalis
Artbeschreibung: Blüten karminrot bis rosa. Lippe 6-9 mm lang und etwa gleich breit, Sporn +/- so lang oder länger als der Fruchtknoten.
Blütezeit: 5-7
Verbreitung global: Westeuropäisch-mediterran
Ökologische Zeigerwerte nach Landolt & al. (2010)
BodenfaktorenKlimafaktorenSalztoleranzFeuchtezahl F--Lichtzahl L--Salzzeichen--Reaktionszahl R--Temperaturzahl T--Nährstoffzahl N--Kontinentalitätszahl K--
Volksname Deutscher Name: Gewöhnliche Spitzorchis Nom français: Orchis pyramidal
description: Published as part of Konrad Lauber, Gerhart Wagner & Andreas Gygax, 2018, Flora Helvetica - Orchidaceae, pp. 1324-1362 in Flora Helvetica, Bern :Haupt Verlag on page 1342
Additional file 1: of Acute pancreatitis after thoracic duct ligation for iatrogenic chylothorax. A case report
Creators: name: Bédat, Benoît
name: Scarpa, Cosimo
name: Sadowski, Samira
name: Triponez, Frédéric
name: Karenovics, Wolfram
Publisher: name: Figshare
Year: 2017
Subjects: subject: Biophysics
subject: Biochemistry
subject: Medicine
subject: Cell Biology
subject: Physiology
subject: FOS: Biological sciences
subject: Biotechnology
subject: 39999 Chemical Sciences not elsewhere classified
subject: FOS: Chemical sciences
subject: Immunology
subject: FOS: Clinical medicine
subject: 69999 Biological Sciences not elsewhere classified
subject: Developmental Biology
subject: Science Policy
subject: Hematology
subject: Infectious Diseases
subject: FOS: Health sciences

description: Description of data : Blood test results 1 day after the onset of the abdominal pain. WBC, white blood count; CRP, C-reactive protein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; γGT, gamma-glutamyl transpeptidase; AP, alkaline phosphatase; IgG, immunoglobulin G. (DOCX 14 kb)
The cost-effectiveness of a bimekizumab versus IL-17A inhibitors treatment-pathway in patients with active axial spondyloarthritis in Scotland
Creators: name: Mørup, Michael F.
name: Taieb, Vanessa
name: Willems, Damon
name: Rose, Micah
name: Lyris, Nikos
name: Lamotte, Mark
name: Gerlier, Laetitia
name: Thom, Howard
Publisher: name: Taylor & Francis
Year: 2024
Subjects: subject: Medicine
subject: Pharmacology
subject: Chemical Sciences not elsewhere classified
subject: Immunology
subject: FOS: Clinical medicine
subject: Biological Sciences not elsewhere classified
subject: Science Policy
subject: Infectious Diseases
subject: FOS: Health sciences

description: To estimate the cost-effectiveness of a treatment-pathway initiated with bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL-17A, in patients with axial spondyloarthritis (axSpA) compared with IL-17Ai's, ixekizumab, and secukinumab, from the NHS Scotland perspective. The axSpA treatment-pathway was modeled using a decision tree followed by a lifetime Markov model. The pathway included first- and second-line biologic disease-modifying antirheumatic drugs (bDMARD), followed by best supportive care (bDMARD, nonbiologic). Bimekizumab followed by any bDMARD (“BKZ”) was compared with IL-17Ai’s: secukinumab 150 mg followed by a blend (“SEC”) of dose up-titration to secukinumab 300 mg and any bDMARD, or ixekizumab followed by any bDMARD (“IXE”). Transition to the next therapy was triggered by Bath Ankylosing Spondylitis Disease Activity Index-50% (BASDAI50) non-response or any-cause discontinuation. A published network meta-analysis provided efficacy data. EuroQoL-5-dimensions utilities were derived by mapping from Ankylosing Spondylitis Disease Activity Score. Costs included disease management (linked to functional limitations), biologics acquisition (list prices), administration and monitoring (NHS 2021/22). Discounting was 3.5%/year. Probabilistic results from patients with non-radiographic axSpA and ankylosing spondylitis were averaged to reflect the axSpA disease spectrum. Scenario and sensitivity analyses were performed. The incremental cost-effectiveness ratio (ICER) of BKZ was £24,801/quality-adjusted life-year (QALY) vs. SEC (95% credible interval £24,163–£25,895). BKZ had similar costs (Δ -£385 [−£15,239–£14,468]) and QALYs (Δ 0.039 [−0.748–0.825]) to IXE, with £1,523 (£862–£2,222) net monetary benefit. Conclusions remained unchanged in most scenarios. Results’ drivers included BASDAI50 response rate and disease management cost. Results were based on list prices. Data concerning up-titration to secukinumab 300 mg was scarce. The bimekizumab treatment-pathway represents a cost-effective option across the axSpA disease spectrum in Scotland. Bimekizumab is cost-effective compared to a secukinumab-pathway that includes dose up-titration, and has similar costs and QALYs to an ixekizumab-pathway.
Additional file 2: Figure S2. of Release of endothelial cell associated VEGFR2 during TGF-β modulated angiogenesis in vitro
Creators: name: M. Jarad
name: E. Kuczynski
name: J. Morrison
name: A. Viloria-Petit
name: B. Coomber
Publisher: name: Figshare
Year: 2017
Subjects: subject: Biochemistry
subject: Medicine
subject: Cell Biology
subject: Pharmacology
subject: 39999 Chemical Sciences not elsewhere classified
subject: FOS: Chemical sciences
subject: Developmental Biology
subject: Cancer

description: ALK5 inhibitor SD-208 prevents TGF-β1 induced downregulation of VEGFR2 expression. Western blots showing impact of increases doses of SD-208 on BAEC treated with DMSO vehicle (0) or 5 ng/ml TGF-β1 for 24 h. (PDF 176 kb)
Additional file 1: Table S3. of Appropriate NH4
                     +: NO3
                     â   ratio improves low light tolerance of mini Chinese cabbage seedlings
Creators: name: Linli Hu
name: Weibiao Liao
name: Dawuda, Mohammed
name: Jihua Yu
name: Lv, Jian
Publisher: name: Figshare
Year: 2017
Subjects: subject: Genetics
subject: FOS: Biological sciences
subject: Physiology
subject: Pharmacology
subject: Marine Biology
subject: Computational Biology

description: Principal components loading matrix of tested traits of mini Chinese cabbage under four ammonium: nitrate ratios and two light fluences. (DOCX 16 kb)
Cost-effectiveness of volume computed tomography in lung cancer screening: a cohort simulation based on nelson study outcomes
Creators: name: Pan, Xuanqi
name: Dvortsin, Evgeni
name: Baldwin, David R
name: Groen, Harry J.M.
name: Ramaker, Dianne
name: Ryan, James
name: Berge, Hilde ten
name: Velikanova, Rimma
name: Oudkerk, Matthijs
name: Postma, Maarten J
Publisher: name: Taylor & Francis
Year: 2023
Subjects: subject: Medicine
subject: Physiology
subject: FOS: Biological sciences
subject: Biotechnology
subject: Sociology
subject: FOS: Sociology
subject: Biological Sciences not elsewhere classified
subject: Cancer
subject: Science Policy

description: Objectives This study aimed to evaluate the cost-effectiveness of lung cancer screening (LCS) with volume-based low-dose computed tomography (CT) versus no screening for an asymptomatic high-risk population in the United Kingdom (UK), utilizing the long-term insights provided by the NELSON study, the largest European randomized control trial investigating LCS. Methods A cost-effectiveness analysis was conducted using a decision tree and a state-transition Markov model to simulate the identification, diagnosis, and treatments for a lung cancer high-risk population, from a UK National Health Service (NHS) perspective. Eligible participants underwent annual volume CT screening and were compared to a cohort without the option of screening. Screen-detected lung cancers, costs, quality-adjusted life years (QALYs), and the incremental cost-effectiveness ratio (ICER) were predicted. Results Annual volume CT screening of 1.3 million eligible participants resulted in 96,474 more lung cancer cases detected in early stage, and 73,825 fewer cases in late stage, leading to 53,732 premature lung cancer deaths averted and 421,647 QALYs gained, compared to no screening. The ICER was £5,455 per QALY. These estimates were robust in sensitivity analyses. Limitations Lack of long-term survival data for lung cancer patients; deficiency in rigorous micro-costing studies to establish detailed treatment costs inputs for lung cancer patients. Conclusions Annual LCS with volume-based low-dose CT for a high-risk asymptomatic population is cost-effective in the UK, at a threshold of £20,000 per QALY, representing an efficient use of NHS resources with substantially improved outcomes for lung cancer patients, as well as additional societal and economic benefits for society as a whole. National LCS is highly recommended to be implemented in the UK.
Additional file 7: Figure S4. of Generation of mesenchymal stromal cells from cord blood: evaluation of in vitro quality parameters prior to clinical use
Creators: name: Amati, Eliana
name: Sella, Sabrina
name: Perbellini, Omar
name: Alghisi, Alberta
name: Bernardi, Martina
name: Chieregato, Katia
name: Lievore, Chiara
name: Peserico, Denise
name: Rigno, Manuela
name: Zilio, Anna
name: Ruggeri, Marco
name: Rodeghiero, Francesco
name: Astori, Giuseppe
Publisher: name: Figshare
Year: 2017
Subjects: subject: Space Science
subject: Cell Biology
subject: Molecular Biology
subject: Pharmacology
subject: Immunology
subject: FOS: Clinical medicine
subject: 69999 Biological Sciences not elsewhere classified
subject: FOS: Biological sciences
subject: Hematology

description: Immunomodulation assay. Flow cytometry analysis of thawed PBMC before (A) and after (B) overnight resting. The percentage of monocytes of one representative sample is shown. (C) Proliferation ratio between the percentage of CD45+ proliferation at primed and resting conditions, at the different MSC passages. Results from two independent experiments against two different PBMC lots are shown. (DOCX 637 kb)
Post-approval indications and clinical trials for cardiovascular drugs and some implications of the US inflation reduction act
Creators: name: Grabowski, Henry
name: Long, Genia
Publisher: name: Taylor & Francis
Year: 2024
Subjects: subject: Medicine
subject: Pharmacology
subject: Cancer
subject: Science Policy
subject: Infectious Diseases
subject: FOS: Health sciences
subject: Virology
subject: Computational Biology

description: Objective To describe the historical baseline landscape of cardiovascular drug post-approval activity, including the number and timing of post-approval clinical trials and approved indications. The US Inflation Reduction Act of 2022 (IRA) Drug Price Negotiation Program (DPNP) and its Maximum Fair Prices (MFPs) will affect incentives for investment in post-approval activity such as clinical trials for new indications. While three of the first ten drugs selected for the DPNP and MFP-setting are cardiovascular or antithrombotic drugs, limited attention has been paid to potential cardiovascular drug impacts, and to post-approval innovation. Methods For the 65 drugs originally approved by the FDA from 1995 through 2021 for a cardiovascular or antithrombotic indication (60 small molecules and 5 biologics), we develop a novel dataset of industry-sponsored, post-approval clinical trials and FDA-approved label changes for new indications. We analyze their number and timing relative to DPNP drug selection and MFP implementation dates, by drug approval-year cohort. Results We find 49% of indications were awarded and 76% of industry-funded clinical trials were completed post-approval, reaching 98% of trials for drugs in the earliest 1995-99 cohort. For the 60 small molecules, 76% of post-approval trials ended five years or more after original drug approval, 65% ended seven or more years after original drug approval (i.e., after potential DPNP selection), and 53% nine or more years after original drug approval (i.e., after potential MFP implementation). Conclusions Post-approval FDA indication approvals and clinical trial starts and primary completion dates often occurred after or near new DPNP selection and MFP implementation dates. This has economic consequences for future investment incentives. Post-approval trials for small molecules, longer-duration trials, and larger-enrollment trials, and post-approval indications focused on limited patient populations and older patients could face particular economic challenges.
Cost-effectiveness of empagliflozin as add-on to standard of care for chronic kidney disease management in the United Kingdom
Creators: name: Ramos, Mafalda
name: Gerlier, Laetitia
name: Uster, Anastasia
name: Muttram, Louise
name: Frankel, Andrew H.
name: Lamotte, Mark
Publisher: name: Taylor & Francis
Year: 2024
Subjects: subject: Medicine
subject: Pharmacology
subject: Sociology
subject: FOS: Sociology
subject: Biological Sciences not elsewhere classified
subject: Marine Biology
subject: Science Policy
subject: Infectious Diseases
subject: FOS: Health sciences

description: The sodium-glucose co-transporter-2 inhibitor empagliflozin was approved for treatment of adults with chronic kidney disease (CKD) on the basis of its demonstrated ability to slow CKD progression and reduce the risk of cardiovascular death. This analysis was performed to assess the cost effectiveness of empagliflozin plus standard of care (SoC) versus SoC alone in the treatment of CKD in the UK. A comprehensive, patient-level CKD progression model that simulates the evolution of risk factors for disease progression based on CKD-specific equations and clinical data was used to project a broad range of CKD-related complications. Patient baseline characteristics, distribution across Kidney Disease Improving Global Outcomes (KDIGO) health states, and changes in estimated glomerular filtration rate (eGFR), urine albumin-creatinine ratio (uACR), and other parameters while on treatment, were derived from the EMPA-KIDNEY trial. UK cost and utilities/disutilities were sourced from the literature. Univariate and probabilistic sensitivity analyses were conducted. Annual discounting of 3.5% was applied on costs and outcomes. Over a 50-year horizon, SoC resulted in per-patient costs, life years, and QALYs of £95,930, 8.55, and 6.28, respectively. Empagliflozin plus SoC resulted in an incremental gain in life years (+1.04) and QALYs (+0.84), while decreasing per-patient costs by £6,019. Empagliflozin was more effective and less costly (dominant) with a net monetary benefit of £22,849 at the willingness-to-pay threshold of £20,000. Although treatment cost was higher for empagliflozin, this was more than offset by savings in kidney replacement therapy. Empagliflozin remained highly cost-effective in patients with and without diabetes, and across scenario and sensitivity analyses. This analysis is limited by reliance on short-term clinical trial data and by uncertainties in modelling CKD progression. Empagliflozin as an add-on to SoC for treatment of adults with CKD represents cost-effective use of UK National Health Service (NHS) resources.
Anacamptis pyramidalis subsp. tanayensis Quentin
Creators: name: Konrad Lauber
name: Gerhart Wagner
name: Andreas Gygax
Publisher: name: Haupt Verlag
Year: 2018
Subjects: Biodiversity
Taxonomy
Plantae
Tracheophyta
Liliopsida
Asparagales
Orchidaceae
Anacamptis
Anacamptis pyramidalis
Anacamptis pyramidalis subsp. tanayensis (chenevard) quentin

description: Anacamptis pyramidalis subsp. tanayensis (Chenevard) Quentin
Artbeschreibung: Blüten kleiner, dunkelpurpurn. Sporn deutlich kürzer als der Fruchtknoten.
Blütezeit: 7-8
Verbreitung global: Westalpin
Ökologische Zeigerwerte nach Landolt & al. (2010)
BodenfaktorenKlimafaktorenSalztoleranzFeuchtezahl F--Lichtzahl L--Salzzeichen--Reaktionszahl R--Temperaturzahl T--Nährstoffzahl N--Kontinentalitätszahl K--
Volksname Deutscher Name: Tanay-Spitzorchis Nom français: Orchis pyramidal de Tanay
description: Published as part of Konrad Lauber, Gerhart Wagner & Andreas Gygax, 2018, Flora Helvetica - Orchidaceae, pp. 1324-1362 in Flora Helvetica, Bern :Haupt Verlag on page 1342
Additional file 8: Figure S5. of Generation of mesenchymal stromal cells from cord blood: evaluation of in vitro quality parameters prior to clinical use
Creators: name: Amati, Eliana
name: Sella, Sabrina
name: Perbellini, Omar
name: Alghisi, Alberta
name: Bernardi, Martina
name: Chieregato, Katia
name: Lievore, Chiara
name: Peserico, Denise
name: Rigno, Manuela
name: Zilio, Anna
name: Ruggeri, Marco
name: Rodeghiero, Francesco
name: Astori, Giuseppe
Publisher: name: Figshare
Year: 2017
Subjects: subject: Biochemistry
subject: Cell Biology
subject: Genetics
subject: FOS: Biological sciences
subject: Molecular Biology
subject: Physiology
subject: Pharmacology
subject: Biotechnology
subject: 39999 Chemical Sciences not elsewhere classified
subject: FOS: Chemical sciences
subject: 69999 Biological Sciences not elsewhere classified
subject: Developmental Biology
subject: Hematology
subject: 110309 Infectious Diseases
subject: FOS: Health sciences

description: Representative array-CGH profiles of the whole genome of one representative LL-CBMSC sample at P5 (lower panel) and P11 (upper panel) (DOCX 107 kb)
Cephalanthera damasonium Druce
Creators: name: Konrad Lauber
name: Gerhart Wagner
name: Andreas Gygax
Publisher: name: Haupt Verlag
Year: 2018
Subjects: Biodiversity
Taxonomy
Plantae
Tracheophyta
Liliopsida
Asparagales
Orchidaceae
Cephalanthera
Cephalanthera damasonium

description: Cephalanthera damasonium (Mill.) Druce
Artbeschreibung: 20-50 cm hoch. Stängel kahl, mit länglich-eiförmigen, umfassenden, ungefalteten Blättern. Untere Tragblätter ähnlich wie die Stängelblätter, obere schmal-lanzettlich, meist länger als der Fruchtknoten. Blütenstand bis 16 blütig. Blüten gelblich-weiss, fast ganz geschlossen bleibend, Perigonblätter stumpf. Lippe vorn gelb.
Blütezeit: 6
Standort und Verbreitung in der Schweiz: Schattige Wälder / kollin-montan / CH (fehlt im Engadin)
Verbreitung global: Europäisch
Ökologische Zeigerwerte nach Landolt & al. (2010)
BodenfaktorenKlimafaktorenSalztoleranzFeuchtezahl Ffrisch; Feuchtigkeit mässig wechselnd (± 1-2 Stufen)Lichtzahl LhalbschattigSalzzeichen--Reaktionszahl Rneutral bis basisch (pH 5.5-8.5)Temperaturzahl Tunter-montan und ober-kollinNährstoffzahl NnährstoffarmKontinentalitätszahl Ksubozeanisch bis subkontinental (mittlere Luftfeuchtigkeit, mässige Temperaturschwankungen und mässig tiefe Wintertemperaturen)
Volksname Deutscher Name: Weisses Waldvögelein, Weisse Kopforche Nom français: Céphalanthère blanche, Céphalanthère de Damas Nome italiano: Cefalantera bianca
description: Published as part of Konrad Lauber, Gerhart Wagner & Andreas Gygax, 2018, Flora Helvetica - Orchidaceae, pp. 1324-1362 in Flora Helvetica, Bern :Haupt Verlag on page 1342
Cephalanthera longifolia Fritsch
Creators: name: Konrad Lauber
name: Gerhart Wagner
name: Andreas Gygax
Publisher: name: Haupt Verlag
Year: 2018
Subjects: Biodiversity
Taxonomy
Plantae
Tracheophyta
Liliopsida
Asparagales
Orchidaceae
Cephalanthera
Cephalanthera longifolia

description: Cephalanthera longifolia (L.) Fritsch
Artbeschreibung: Ähnlich wie C. damasonium, aber Blätter lineal-lanzettlich, gefaltet und 2zeilig angeordnet, Tragblätter meist viel kürzer als der Fruchtknoten, Blütenstand bis über 30 blütig. Perigonblätter reinweiss, spitz, weniger zusammenneigend.
Blütezeit: 5-6
Standort und Verbreitung in der Schweiz: Bergwiesen, Waldlichtungen, Föhrenwälder / kollin-montan / CH
Verbreitung global: Eurasiatisch
Ökologische Zeigerwerte nach Landolt & al. (2010)
BodenfaktorenKlimafaktorenSalztoleranzFeuchtezahl Ffrisch; Feuchtigkeit stark wechselnd (mehr als ± 2 Stufen)Lichtzahl LhalbschattigSalzzeichen--Reaktionszahl Rneutral bis basisch (pH 5.5-8.5)Temperaturzahl Tunter-montan und ober-kollinNährstoffzahl NnährstoffarmKontinentalitätszahl Ksubkontinental (niedrige relative Luftfeuchtigkeit, grosse Temperaturschwankungen, eher kalte Winter)
Volksname Deutscher Name: Langblättriges Waldvögelein, Langblättrige Kopforche Nom français: Céphalanthère à longues feuilles Nome italiano: Cefalantera maggiore
description: Published as part of Konrad Lauber, Gerhart Wagner & Andreas Gygax, 2018, Flora Helvetica - Orchidaceae, pp. 1324-1362 in Flora Helvetica, Bern :Haupt Verlag on page 1342
Le projet Richelieu - Histoire du quartier
Creators: name: Kervegan, Paul
name: Duvette, Charlotte
Publisher: name: Zenodo
Year: 2024
Subjects: réutilisation
science ouverte
données de recherche
annotation
patrimoine

description: Cette présentation a été réalisée lors du webinaire du jeudi 28 mars 2024, organisé par le GTSO Données de Couperin. Lors de ce webinaire, Réutiliser des données, ils et elles l'ont fait ! Paroles de lauréats du prix Science Ouverte données de la recherche, 4 lauréats et lauréates du prix Science Ouverte des données de la recherche, mention « réutilisation de données » sont revenus sur leur projet et sur la manière dont la mise à disposition de jeux de données ouverts par d’autres ont permis de donner naissance à de nouveaux projets de recherche. https://gtsodataweb8.sciencesconf.org/

L’enregistrement est disponible ici : https://www.youtube.com/watch?v=MZtkSzEnG34